Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/en/news-release/2024/07/09/2910200/0/en/Kymera-Therapeutics-to-Present-in-Fireside-Chat-at-the-UBS-Virtual-Targeted-Protein-Degradation-Day.html
https://www.globenewswire.com/news-release/2024/07/08/2909952/0/en/Kymera-Announces-Expansion-of-KT-474-SAR444656-HS-and-AD-Phase-2-Studies-Following-Interim-Review-of-Safety-and-Efficacy.html
https://www.globenewswire.com/news-release/2024/06/14/2898896/0/en/Kymera-Therapeutics-Presents-New-Clinical-Data-from-the-Ongoing-Phase-1-Trial-of-STAT3-Degrader-KT-333-at-EHA-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/06/01/2891812/0/en/Kymera-Therapeutics-Presents-New-Clinical-Data-from-Ongoing-Phase-1-Trial-of-MDM2-Degrader-KT-253-at-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/29/2889687/0/en/Kymera-Therapeutics-to-Participate-in-Upcoming-June-Investor-Conferences.html
https://www.globenewswire.com/news-release/2024/05/23/2887688/0/en/Kymera-Therapeutics-to-Present-New-Clinical-Data-from-Ongoing-Phase-1-Trial-of-MDM2-Degrader-KT-253-at-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/22/2886703/0/en/Kymera-Therapeutics-Presents-New-Preclinical-Data-for-KT-621-a-First-In-Class-Oral-STAT6-Degrader-at-the-ATS-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/14/2881550/0/en/Kymera-Therapeutics-to-Present-New-Clinical-Data-from-the-Ongoing-Phase-1-Trial-of-STAT3-Degrader-KT-333-at-EHA-Annual-Meeting.html
https://www.biotechnewswire.ai/202405142541/neosphere-biotechnologies-partners-with-kymera-therapeutics-for-novel-molecular-glue-target-discovery.html
https://www.globenewswire.com/news-release/2024/05/08/2877663/0/en/Kymera-Therapeutics-to-Participate-in-Upcoming-May-Investor-Conferences.html